ESMO 2023 BioNTech Data slide image

ESMO 2023 BioNTech Data

BNT314/GEN10591 - Designed to Boost Antitumor Immune Response Through EpCAM-Dependent 4-1BB Agonistic Activity Antitumor activity in human EpCAM-transgenic mice. Fellermeier-Kopf et al. Presented at ESMO 2023. #1072P Tumor volume (mm³) Tumor volumes over time 1,000 800 600 400 200 Percent survival Kaplan-Meier analysis of survival 100 80 60 60 10 10 20 0 0 7 14 21 28 Days after tumor inoculation B ] ** **** mbslgG2a-hEpCAM xm4-1BB Isotype control 0 0 7 14 21 28 35 42 49 Days after tumor inoculation 56 63 mbslgG2a-hEpCAM xm4-1BB Isotype control Results suggest that BNT314/GEN1059 may boost antitumor immunity in cancer patients with EpCAM + tumors. ] ** The clinical safety and preliminary antitumor activity of DuoBody-EpCAMx4-1BB will be investigated in patients with solid tumors in a first-in-human trial. 1. BNT314 (GEN1059) is partnered with Genmab based on 50/50 sharing of costs and profits.. EpCAM epithelial cell adhesion molecule 5 BIONTECH
View entire presentation